申请人:Kyowa Hakko Kirin Co., Ltd.
公开号:EP2070927A1
公开(公告)日:2009-06-17
A fused heterocycle derivative represented by the general formula (I):
(wherein R1 represents optionally substituted lower alkyl, or the like; R2 represents an optionally substituted aliphatic heterocyclic group, or the like; R3 represents -C(=Z)NR5R6 (wherein R5 and R6 represent optionally substituted lower alkyl, or the like, and Z represents an oxygen atom or the like), or the like; n represents an integer of 1 to 3; and W represents C-R5 (wherein R5 represents a hydrogen atom or the like)) or a pharmaceutically acceptable salt thereof, and the like are provided.
通式 (I) 所代表的融合杂环衍生物:
(其中 R1 代表任选取代的低级烷基或类似物;R2 代表任选取代的脂肪杂环基团或类似物;R3 代表-C(=Z)NR5R6(其中 R5 和 R6 代表任选取代的低级烷基或类似物,Z 代表氧原子或类似物)或类似物;n 代表 1 至 3 的整数;W 代表 C-R5(其中 R5 代表氢原子或类似物))或其药学上可接受的盐等。